TIAA CREF Investment Management’s Niagen Bioscience NAGE Stock Holding History

TIAA CREF Investment Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$206K	Hold	49,224	–	–	﹤0.01%	2879
2018 Q4	$169K	Hold	49,224	–	–	﹤0.01%	2904
2018 Q3	$211K	Sell	49,224 -9,802	-17%	-$42.1K	﹤0.01%	2968
2018 Q2	$219K	Buy	+59,026	New	+$224K	﹤0.01%	3020
2017 Q2	–	Sell	-81,255	Closed	-$219K	–	3185
2017 Q1	$219K	Sell	81,255 -2,794	-3%	-$7.92K	﹤0.01%	2978
2016 Q4	$278K	Buy	84,049 +9	+0%	+$24	﹤0.01%	2990
2016 Q3	$250	Hold	84,040	–	–	﹤0.01%	3025
2016 Q2	$348K	Buy	+84,040	New	+$398K	﹤0.01%	2997

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

TIAA CREF Investment Management's NAGE Position: Q1 2019 in Review

TIAA CREF Investment Management held its Niagen Bioscience (NAGE) position steady in Q1 2019 at 49,224 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #2879.

TIAA CREF Investment Management first reported a position in NAGE in Q2 2016 and has held it in 8 quarters since. The position peaked at $348K in Q2 2016. 58 funds tracked by Wall St. Rank hold NAGE as of Q1 2019.

TIAA CREF Investment Management held 49,224 shares of Niagen Bioscience worth $206K as of Q1 2019.
TIAA CREF Investment Management left its Niagen Bioscience share count unchanged in Q1 2019.
Niagen Bioscience made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2879 holding.
TIAA CREF Investment Management first reported a position in Niagen Bioscience in Q2 2016 and has held it in 8 quarters since.
TIAA CREF Investment Management's Niagen Bioscience position peaked at $348K in Q2 2016.
58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.